-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Biohaven Pharma (BHVN), "no change to outlook"
-
-
-
-
-
-
-
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright
-
-
-
-
-
-
-
RBC Capital Upgrades Biohaven Pharma (BHVN) to Outperform
-
-
-
-
-
-
-
H.C. Wainwright Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


